NORTHBROOK, Ill., July 31, 2018 (GLOBE NEWSWIRE) — Immunomodulation Inc. (“Immunomodulation” or the “Company”), a privately-held biopharmaceutical company focused on developing breakthrough therapies to modulate immune responses in multiple high-value oncology and serious infectious diseases, today announced the formation of its Scientific Advisory Board (SAB) and appointment of Robert V. Stahelin, Ph.D., to the SAB.
Immunomodulation expects to add additional members to its SAB in the coming months. The SAB will work closely with the Immunomodulation team as it advances its lead product candidate, IMM-010 towards human clinical studies over the next 18-months.
“We are pleased to welcome Dr. Stahelin as the inaugural member to our SAB. We believe that his experience and expertise will be a valuable asset to Immunomodulation as he will work closely with our team in guiding the development of IMM-010,” commented Dr. Michael Beaubaire, Chief Executive Officer of Immunomodulation. “Importantly, the formation of our SAB serves as an endorsement for scientific and clinical enthusiasm for IMM-010 while providing critical development guidance to more broadly address its potential for the significant unmet needs in well-established and growing markets.”
Dr. Stahelin is an established academic expert with a specialization in biochemistry and biophysics and currently serves as Retter Professor of Pharmacy, Professor of Medicinal Chemistry and Molecular Pharmacology at Purdue University. Prior to his appointment at Purdue University, Dr. Stahelin held a number of academic positions including Co-director, Integrated Biomedical Sciences (IBMS) Graduate Program at University of Notre Dame, Navari Family Scholar and Associate Professor of Biochemistry & Molecular Biology at the Indiana University School of Medicine, Interim Senior Associate Director, Harper Cancer Research Institute, Indiana University School of Medicine-South Bend and the University of Notre Dame and Associate Professor of Biochemistry & Molecular Biology, Indiana University School of Medicine. Over the course of his academic career, Dr. Stahelin has received a number of professional honors and awards for both his research and teaching including the IUSM Showalter Scholar Award and has mentored more than ten Ph.D. students, five postdocs, several MS students, and more than 20 undergraduates. He has served as a member of a number of organizations such as the American Chemical Society and the American Heart Association Basic Science Council, and currently serves as a member of the Biophysical Society and the American Society for Biochemistry and Molecular Biology. He has received and completed 20 research grants/fellowships, is an active speaker and has an extensive review and publication library including authorship of over 100 academic papers. Dr. Stahelin’s interdisciplinary research is focused on biological membranes which have been revealed as signaling and trafficking platforms for processes fundamental to life.
“I am excited to join the Immunomodulation SAB at this important time for the Company. I believe in IMM-010’s potential as a breakthrough therapy for specific, serious infectious diseases with limited if any treatment options. Exploring annexin v’s effect on membrane signaling to engage the immune system is exciting. I look forward to playing an integral role in advancing IMM-010,” stated Dr. Stahelin.
Dr. Stahelin received his B.S. in Biochemistry and Ph.D. in Chemistry from the University of Illinois at Chicago.
About Immunomodulation
Immunomodulation is a privately-held biopharmaceutical company focused on developing breakthrough therapies to modulate immune responses in multiple high value oncology and serious infectious disease indications.
The Company’s lead program, IMM-010 (annexin V) is in preclinical development for the treatment of solid tumors and certain viruses and has the potential for additional pipeline expansion opportunities. IMM-010 binds to phosphatidylserine (PS) on tumor cells and infective organisms. IMM-010 has been demonstrated to be effective in generating immune responses and has shown both tumor size reduction and anti-infective effects in animal models of diseases. Immunomodulation, working in collaboration with a network of leading institutions, is sponsoring research and manufacturing to drive the execution of its development plan. Based on previous clinical experience of the Company’s founders with annexin-V as an imaging agent, Immunomodulation expects to file an IND for IMM-010 in less than 18 months. For more information please visit www.immunomodulation.com.
Forward-Looking Statements
This press release contains certain forward-looking statements, including those relating to the Company’s product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable and complete. However, a variety of factors, many of which are beyond the Company’s control, affect the Company’s operations, performance, business strategy and results and there can be no assurances that the Company’s actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
(833) 475-8247
imod@jtcir.com
